PHXM Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.96 |
| 52 Week High | €11.70 |
| 52 Week Low | €2.60 |
| Beta | 1.79 |
| 1 Month Change | -0.67% |
| 3 Month Change | -21.28% |
| 1 Year Change | -59.84% |
| 3 Year Change | -95.11% |
| 5 Year Change | -95.70% |
| Change since IPO | -97.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHXM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 1.4% | -2.9% | -1.5% |
| 1Y | -59.8% | -4.3% | 3.4% |
Return vs Industry: PHXM underperformed the French Biotechs industry which returned -4.4% over the past year.
Return vs Market: PHXM underperformed the French Market which returned 3% over the past year.
Price Volatility
| PHXM volatility | |
|---|---|
| PHXM Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: PHXM's share price has been volatile over the past 3 months.
Volatility Over Time: PHXM's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| PHXM fundamental statistics | |
|---|---|
| Market cap | €17.98m |
| Earnings (TTM) | -€23.49m |
| Revenue (TTM) | €1.33m |
13.6x
P/S Ratio-0.8x
P/E RatioIs PHXM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHXM income statement (TTM) | |
|---|---|
| Revenue | €1.33m |
| Cost of Revenue | €0 |
| Gross Profit | €1.33m |
| Other Expenses | €24.81m |
| Earnings | -€23.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,771.34% |
| Debt/Equity Ratio | 39.8% |
How did PHXM perform over the long term?
See historical performance and comparison